Intraosseous Versus Submucosal Dexamethsone Injection in Third Molar Surgery

Launched by SERVICES INSTITUTE OF MEDICAL SCIENCES, PAKISTAN · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to give a medication called dexamethasone to patients having their wisdom teeth (third molars) removed. The researchers want to find out if injecting dexamethasone directly into the bone (intraosseous) is more effective in reducing pain and swelling after surgery compared to injecting it under the gum (submucosal). They will also check if this method helps patients open their mouths wider after the procedure. Participants will be monitored on the 3rd and 7th day after surgery to assess their pain levels, swelling, and mouth opening.

To be eligible for this study, participants must be between 18 and 35 years old and scheduled for wisdom teeth surgery. However, individuals with certain health issues, like uncontrolled diabetes or high blood pressure, or those with specific dental conditions or past medical treatments that could affect the results are not eligible. This trial is not yet recruiting, but it aims to provide important information that could improve post-surgery care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing mandibular third molar surgery
• • Age 18 to 35 years
• • Male and female
• Exclusion Criteria:
• • Uncontrolled systemic medical problems including diabetes and hypertension
• • Presence of any cyst, tumor, or other pathological condition in the molar area
• • Presence of any craniofacial anomalies, congenital deformities or syndromes
• • Patients with known adverse effects of steroid use
• • Previous history of orthodontic treatment
• • Have a pain disorder or taking pain medications
• • Pregnant and lactating mothers